Aurinia Pharmaceuticals Inc. (AUPH)
USD 7.8
(-3.17%)
USD 7.8
(-3.17%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 48.73 Million USD | 156.61% |
| 2022 | -86.08 Million USD | 61.43% |
| 2021 | -223.16 Million USD | 15.45% |
| 2020 | -263.94 Million USD | 13.75% |
| 2019 | -306.01 Million USD | -159.41% |
| 2018 | -117.96 Million USD | 28.78% |
| 2017 | -165.62 Million USD | -317.74% |
| 2016 | -39.64 Million USD | -588.83% |
| 2015 | -5.75 Million USD | 74.65% |
| 2014 | -22.7 Million USD | -4430.58% |
| 2013 | -501.17 Thousand USD | -236.88% |
| 2012 | -148.76 Thousand USD | 97.45% |
| 2011 | -5.84 Million USD | 7.94% |
| 2010 | -6.34 Million USD | -38.51% |
| 2009 | -4.58 Million USD | 44.04% |
| 2008 | -8.18 Million USD | 74.18% |
| 2007 | -31.72 Million USD | -187.7% |
| 2006 | -11.02 Million USD | 13.46% |
| 2005 | -12.74 Million USD | -27.29% |
| 2004 | -10 Million USD | 63.2% |
| 2003 | -27.19 Million USD | -38.83% |
| 2002 | -19.59 Million USD | 36.13% |
| 2001 | -30.67 Million USD | -488.23% |
| 2000 | -5.21 Million USD | -113.3% |
| 1999 | -2.44 Million USD | -1038.79% |
| 1998 | 260.41 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 24.07 Million USD | -50.59% |
| 2024 Q2 | 52.57 Million USD | 118.36% |
| 2023 Q3 | 46.81 Million USD | 140.1% |
| 2023 FY | 48.73 Million USD | 156.61% |
| 2023 Q4 | 48.73 Million USD | 4.09% |
| 2023 Q1 | -81.07 Million USD | 5.82% |
| 2023 Q2 | 19.49 Million USD | 124.05% |
| 2022 Q1 | -123.97 Million USD | 44.45% |
| 2022 Q2 | -143.24 Million USD | -15.55% |
| 2022 Q3 | -77.86 Million USD | 45.64% |
| 2022 Q4 | -86.08 Million USD | -10.56% |
| 2022 FY | -86.08 Million USD | 61.43% |
| 2021 Q3 | -48.68 Million USD | 56.78% |
| 2021 FY | -223.16 Million USD | 15.45% |
| 2021 Q1 | -147.71 Million USD | 44.04% |
| 2021 Q2 | -112.62 Million USD | 23.75% |
| 2021 Q4 | -223.16 Million USD | -358.41% |
| 2020 Q3 | -240.46 Million USD | 6.85% |
| 2020 Q2 | -258.14 Million USD | 3.8% |
| 2020 Q4 | -263.94 Million USD | -9.77% |
| 2020 FY | -263.94 Million USD | 13.75% |
| 2020 Q1 | -268.35 Million USD | 12.31% |
| 2019 Q3 | -134.16 Million USD | -2.35% |
| 2019 Q1 | -139.93 Million USD | -18.62% |
| 2019 Q4 | -306.01 Million USD | -128.1% |
| 2019 FY | -306.01 Million USD | -159.41% |
| 2019 Q2 | -131.08 Million USD | 6.33% |
| 2018 Q2 | -132.3 Million USD | -0.82% |
| 2018 FY | -117.96 Million USD | 28.78% |
| 2018 Q3 | -114.89 Million USD | 13.15% |
| 2018 Q4 | -117.96 Million USD | -2.67% |
| 2018 Q1 | -131.22 Million USD | 20.77% |
| 2017 Q1 | -199.06 Million USD | -402.07% |
| 2017 Q2 | -179.71 Million USD | 9.72% |
| 2017 Q4 | -165.62 Million USD | -89.19% |
| 2017 Q3 | -87.54 Million USD | 51.29% |
| 2017 FY | -165.62 Million USD | -317.74% |
| 2016 Q2 | -9.12 Million USD | -161.31% |
| 2016 FY | -39.64 Million USD | -588.83% |
| 2016 Q1 | -3.49 Million USD | 39.33% |
| 2016 Q3 | -12.33 Million USD | -35.16% |
| 2016 Q4 | -39.64 Million USD | -221.49% |
| 2015 Q3 | -10.59 Million USD | 32.64% |
| 2015 Q2 | -15.72 Million USD | 17.4% |
| 2015 Q1 | -19.04 Million USD | 16.14% |
| 2015 FY | -5.75 Million USD | 74.65% |
| 2015 Q4 | -5.75 Million USD | 45.67% |
| 2014 Q3 | -25.53 Million USD | 34.69% |
| 2014 FY | -22.7 Million USD | -4430.58% |
| 2014 Q2 | -39.09 Million USD | 9.69% |
| 2014 Q1 | -43.28 Million USD | -8537.55% |
| 2014 Q4 | -22.7 Million USD | 11.07% |
| 2013 Q2 | -431.49 Thousand USD | -7217.16% |
| 2013 Q1 | -5897.00 USD | 96.04% |
| 2013 FY | -501.17 Thousand USD | -236.88% |
| 2013 Q4 | -501.17 Thousand USD | 88.85% |
| 2013 Q3 | -4.49 Million USD | -941.52% |
| 2012 Q3 | -239.77 Thousand USD | 81.44% |
| 2012 Q2 | -1.29 Million USD | 60.56% |
| 2012 Q1 | -3.27 Million USD | 43.95% |
| 2012 FY | -148.76 Thousand USD | 97.45% |
| 2012 Q4 | -148.76 Thousand USD | 37.96% |
| 2011 Q3 | -7.33 Million USD | 15.16% |
| 2011 Q2 | -8.64 Million USD | 15.04% |
| 2011 Q1 | -10.17 Million USD | -60.25% |
| 2011 FY | -5.84 Million USD | 7.94% |
| 2011 Q4 | -5.84 Million USD | 20.3% |
| 2010 Q3 | -6.56 Million USD | -64.83% |
| 2010 Q1 | -5.06 Million USD | -10.59% |
| 2010 FY | -6.34 Million USD | -38.51% |
| 2010 Q4 | -6.34 Million USD | 3.25% |
| 2010 Q2 | -3.98 Million USD | 21.47% |
| 2009 Q4 | -4.58 Million USD | 21.63% |
| 2009 FY | -4.58 Million USD | 44.04% |
| 2009 Q3 | -5.84 Million USD | 6.53% |
| 2009 Q2 | -6.25 Million USD | -497.18% |
| 2009 Q1 | -1.04 Million USD | 87.21% |
| 2008 Q1 | -20.53 Million USD | 35.29% |
| 2008 FY | -8.18 Million USD | 74.18% |
| 2008 Q3 | -13.63 Million USD | 18.92% |
| 2008 Q4 | -8.18 Million USD | 39.94% |
| 2008 Q2 | -16.81 Million USD | 18.09% |
| 2007 Q2 | -38.9 Million USD | 1.8% |
| 2007 FY | -31.72 Million USD | -187.7% |
| 2007 Q4 | -31.72 Million USD | 8.84% |
| 2007 Q3 | -34.79 Million USD | 10.54% |
| 2007 Q1 | -39.61 Million USD | -259.24% |
| 2006 Q1 | -11.1 Million USD | 12.85% |
| 2006 Q4 | -11.02 Million USD | 14.58% |
| 2006 Q3 | -12.9 Million USD | -8.53% |
| 2006 FY | -11.02 Million USD | 13.46% |
| 2006 Q2 | -11.89 Million USD | -7.11% |
| 2005 Q3 | -15.5 Million USD | -206.57% |
| 2005 Q1 | -7.75 Million USD | 22.57% |
| 2005 FY | -12.74 Million USD | -27.29% |
| 2005 Q4 | -12.74 Million USD | 17.8% |
| 2005 Q2 | -5.05 Million USD | 34.76% |
| 2004 Q4 | -10 Million USD | 42.03% |
| 2004 Q3 | -17.26 Million USD | 30.33% |
| 2004 FY | -10 Million USD | 63.2% |
| 2004 Q2 | -24.78 Million USD | -18.71% |
| 2004 Q1 | -20.87 Million USD | 23.24% |
| 2003 Q1 | -17.04 Million USD | 13.02% |
| 2003 FY | -27.19 Million USD | -38.83% |
| 2003 Q3 | -41.81 Million USD | -28.05% |
| 2003 Q4 | -27.19 Million USD | 34.95% |
| 2003 Q2 | -32.65 Million USD | -91.61% |
| 2002 FY | -19.59 Million USD | 36.13% |
| 2002 Q3 | -39.16 Million USD | 5.01% |
| 2002 Q1 | -30.01 Million USD | 0.0% |
| 2002 Q2 | -41.22 Million USD | -37.34% |
| 2002 Q4 | -19.59 Million USD | 49.97% |
| 2001 Q2 | -1.83 Million USD | 80.56% |
| 2001 Q3 | -16.72 Million USD | -813.35% |
| 2001 Q1 | -9.41 Million USD | -80.59% |
| 2001 FY | -30.67 Million USD | -488.23% |
| 2000 Q2 | -10.34 Million USD | -275.27% |
| 2000 Q3 | -10.15 Million USD | 1.81% |
| 2000 Q1 | -2.75 Million USD | -12.76% |
| 2000 Q4 | -5.21 Million USD | 48.66% |
| 2000 FY | -5.21 Million USD | -113.3% |
| 1999 Q3 | 66.91 Thousand USD | -93.42% |
| 1999 Q2 | 1.01 Million USD | 253.46% |
| 1999 Q1 | -662.91 Thousand USD | 0.0% |
| 1999 Q4 | -2.44 Million USD | -3753.8% |
| 1999 FY | -2.44 Million USD | -1038.79% |
| 1998 FY | 260.41 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 187.115% |
| Alkermes plc | -166.73 Million USD | 129.227% |
| Agenus Inc. | 274.13 Million USD | 82.223% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 97.394% |
| Aptorum Group Limited | 1.35 Million USD | -3491.035% |
| Ardelyx, Inc. | 34.51 Million USD | -41.203% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | -1038.598% |
| Bicycle Therapeutics plc | -481.46 Million USD | 110.122% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | -34.757% |
| ChromaDex Corporation | -24.04 Million USD | 302.645% |
| Chimerix, Inc. | -25.51 Million USD | 290.979% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -599.361% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 305.82% |
| CRISPR Therapeutics AG | -150.84 Million USD | 132.306% |
| Precision BioSciences, Inc. | -85.41 Million USD | 157.057% |
| Dyadic International, Inc. | -6.37 Million USD | 864.052% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 405.856% |
| Fortress Biotech, Inc. | 7.66 Million USD | -535.773% |
| Lantern Pharma Inc. | -21.7 Million USD | 324.538% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 144.087% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 670.42% |
| Incyte Corporation | -3.17 Billion USD | 101.535% |
| IO Biotech, Inc. | -140.69 Million USD | 134.636% |
| Jaguar Health, Inc. | 29.39 Million USD | -65.806% |
| Novavax, Inc. | -298.29 Million USD | 116.337% |
| Janux Therapeutics, Inc. | 5.33 Million USD | -813.097% |
| Opthea Limited | 28.15 Million USD | -73.07% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 390.261% |
| ContextLogic Inc. | -232 Million USD | 121.005% |
| MiMedx Group, Inc. | -33.9 Million USD | 243.748% |
| Pyxis Oncology, Inc. | 10.19 Million USD | -377.999% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 2203.212% |
| NextCure, Inc. | -6.47 Million USD | 852.385% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 196.497% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 863.944% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | -300.649% |
| Vaxcyte, Inc. | -368.22 Million USD | 113.234% |
| PDS Biotechnology Corporation | -32.7 Million USD | 248.987% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | -182.047% |
| Pharming Group N.V. | 109.8 Million USD | 55.619% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 380.133% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 127.81% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 363.134% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 363.134% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 786.366% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 931.604% |
| Acelyrin, Inc. | -216.9 Million USD | 122.467% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 968.622% |
| SELLAS Life Sciences Group, Inc. | -1.72 Million USD | 2926.682% |
| Summit Therapeutics Inc. | 34.67 Million USD | -40.543% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 816.331% |
| Senti Biosciences, Inc. | 1.74 Million USD | -2700.69% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 126.398% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 162.92% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 903.893% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | -48744.832% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | -7659.873% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 141.635% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 128.967% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 56.046% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 741.548% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 137.743% |
| Psyence Biomedical Ltd. | 6.89 Million USD | -606.814% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 120.107% |
| Immix Biopharma, Inc. | -17.5 Million USD | 378.313% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 115.387% |
| MEI Pharma, Inc. | -3.7 Million USD | 1415.304% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | -289.513% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 69.871% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | -75.339% |
| Fortress Biotech, Inc. | 7.66 Million USD | -535.773% |
| Precigen, Inc. | -481 Thousand USD | 10231.393% |
| Clearside Biomedical, Inc. | 14.08 Million USD | -246.083% |
| AlloVir, Inc. | -62.69 Million USD | 177.732% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 187.625% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 20.974% |
| ImmuCell Corporation | 10.99 Million USD | -343.399% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 131.614% |
| Onconetix, Inc. | 5.33 Million USD | -814.05% |
| PureTech Health plc | -167.19 Million USD | 129.146% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 259.987% |
| Elevation Oncology, Inc. | -19.11 Million USD | 354.901% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 1092.707% |
| Seer, Inc. | -4.24 Million USD | 1249.34% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 302.737% |
| Innoviva, Inc. | 255.56 Million USD | 80.932% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 187.233% |
| ESSA Pharma Inc. | -33.62 Million USD | 244.943% |
| GlycoMimetics, Inc. | -40.98 Million USD | 218.904% |
| GT Biopharma, Inc. | -1.02 Million USD | 4872.968% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 171.894% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 20.447% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 136.346% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 451.703% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 268.786% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | 64787.923% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 257.903% |
| Aptose Biosciences Inc. | -8.19 Million USD | 694.666% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 1657.422% |
| Soligenix, Inc. | -4.95 Million USD | 1084.167% |
| Century Therapeutics, Inc. | 847 Thousand USD | -5653.483% |
| Kura Oncology, Inc. | -20.11 Million USD | 342.231% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 219.073% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 680.281% |
| Ocean Biomedical, Inc. | 1.82 Million USD | -2575.091% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 1624.304% |
| Autolus Therapeutics plc | -186.59 Million USD | 126.116% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 198.84% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 117.67% |
| Eterna Therapeutics Inc. | 34.26 Million USD | -42.208% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 70.352% |
| GRI Bio, Inc. | -1.79 Million USD | 2816.388% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 642.489% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 246.532% |
| IGM Biosciences, Inc. | -72.6 Million USD | 167.118% |
| INmune Bio, Inc. | -25.41 Million USD | 291.775% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 67.717% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 196.196% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 399.901% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 1789.194% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | -28.192% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 218.325% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -52.837% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 87.106% |
| Verastem, Inc. | -37.27 Million USD | 230.726% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 637.11% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 193.965% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 421.982% |
| Histogen Inc. | -7.48 Million USD | 750.888% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 325.54% |
| Surrozen, Inc. | -32.66 Million USD | 249.192% |
| Organovo Holdings, Inc. | -1.5 Million USD | 3333.709% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 1259.323% |
| Ovid Therapeutics Inc. | 18.96 Million USD | -157.022% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -1762.844% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | -1072.57% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 681.448% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 212.177% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 434.311% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 115.383% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | 6849.024% |
| Apollomics, Inc. | -27.39 Million USD | 277.886% |
| Amarin Corporation plc | -191.04 Million USD | 125.509% |
| Mesoblast Limited | 55.96 Million USD | 12.921% |
| Turnstone Biologics Corp. | -14.58 Million USD | 434.147% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 292.678% |
| Synaptogenix, Inc. | -28.66 Million USD | 270.026% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | 5306.41% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 5752.781% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 770.678% |
| Exelixis, Inc. | -73.05 Million USD | 166.71% |
| Better Therapeutics, Inc. | -860 Thousand USD | 5766.512% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 302.94% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 120.19% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -6520.602% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 755.164% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -3786.124% |
| Gritstone bio, Inc. | 39.49 Million USD | -23.403% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 157.945% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 1951.421% |
| Avid Bioservices, Inc. | 169.72 Million USD | 71.288% |
| Insmed Incorporated | 721.62 Million USD | 93.247% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 633.085% |
| MediWound Ltd. | -5.32 Million USD | 1015.671% |
| OmniAb, Inc. | 9.2 Million USD | -429.523% |
| Alector, Inc. | -35.63 Million USD | 236.746% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 43.316% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 1088.88% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | -268.094% |
| Zai Lab Limited | -775 Million USD | 106.288% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 85.69% |
| Aura Biosciences, Inc. | -21.52 Million USD | 326.397% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 159.083% |
| Immunic, Inc. | -45.34 Million USD | 207.481% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 125.222% |
| Veracyte, Inc. | -203.82 Million USD | 123.909% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 92.365% |
| FibroGen, Inc. | 56.76 Million USD | 14.154% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -447.243% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 1823.756% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 2453.807% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 98.938% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 1558.605% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 129.363% |
| TG Therapeutics, Inc. | 17.86 Million USD | -172.825% |
| Galecto, Inc. | -21.21 Million USD | 329.695% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 304.885% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 96.895% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 299.134% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 523.499% |
| XBiotech Inc. | -200.02 Million USD | 124.363% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 157.945% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | -976.237% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 238.196% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 163.11% |
| Theravance Biopharma, Inc. | 5.69 Million USD | -756.299% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 128.596% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 152.755% |
| Vaxxinity, Inc. | 10.13 Million USD | -380.971% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 93.381% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 552.582% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 173.886% |
| NexImmune, Inc. | -3.13 Million USD | 1655.123% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 1511.428% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 422.484% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 279.823% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 642.911% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 39218.603% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 220.112% |
| Ainos, Inc. | 4.07 Million USD | -1095.019% |
| Pluri Inc. | 22.82 Million USD | -113.465% |
| Prothena Corporation plc | -608.34 Million USD | 108.011% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 141.035% |
| Celularity Inc. | 65.19 Million USD | 25.246% |
| Rallybio Corporation | -24.1 Million USD | 302.191% |
| Cue Biopharma, Inc. | -33.81 Million USD | 244.097% |
| MeiraGTx Holdings plc | -40.3 Million USD | 220.917% |
| Omeros Corporation | 331.17 Million USD | 85.285% |
| Humacyte, Inc. | -22.48 Million USD | 316.722% |
| Immunocore Holdings plc | -358.59 Million USD | 113.59% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 298.299% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 257.704% |
| Blueprint Medicines Corporation | 702.83 Million USD | 93.066% |
| CalciMedica, Inc. | -5.53 Million USD | 981.23% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 125.891% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 577.11% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 221.717% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 246.549% |
| Pulmatrix, Inc. | -10.41 Million USD | 567.812% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 915.325% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 227.765% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 143.744% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 181.296% |
| Cytokinetics, Incorporated | 642.37 Million USD | 92.414% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 936.888% |
| Nutriband Inc. | -251.65 Thousand USD | 19464.452% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 242.83% |
| Vor Biopharma Inc. | 4.3 Million USD | -1033.302% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 100.807% |
| Evogene Ltd. | -19.63 Million USD | 348.202% |
| ProKidney Corp. | -56.23 Million USD | 186.656% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 200.123% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 627.563% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 96.427% |
| CorMedix Inc. | -43.05 Million USD | 213.192% |
| BioLineRx Ltd. | 7.33 Million USD | -564.286% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 277.433% |
| Galectin Therapeutics Inc. | 46.14 Million USD | -5.602% |
| Atai Life Sciences N.V. | -28.55 Million USD | 270.642% |
| Renovaro Biosciences Inc. | 2.23 Million USD | -2084.773% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 313.587% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | -174.779% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 164.912% |
| MediciNova, Inc. | -50.78 Million USD | 195.96% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 161.839% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 216734.808% |
| GeoVax Labs, Inc. | -6.45 Million USD | 855.232% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 124.388% |
| Biomea Fusion, Inc. | -166.57 Million USD | 129.256% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 127.228% |
| Mereo BioPharma Group plc | -51.46 Million USD | 194.682% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 151.381% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 116.589% |
| Absci Corporation | -72.59 Million USD | 167.126% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -967.28% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 120.787% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 151.726% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 150.924% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 224.72% |
| Allakos Inc. | -24.97 Million USD | 295.123% |
| Imunon, Inc. | -4.21 Million USD | 1256.472% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 430.566% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 135.991% |
| BioAtla, Inc. | -109.01 Million USD | 144.704% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | -6520.602% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 5289.776% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | -307.254% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 329.835% |
| XOMA Corporation | -29 Million USD | 268.041% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 394.275% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 640.506% |
| aTyr Pharma, Inc. | -7.44 Million USD | 754.209% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 139.099% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 123.41% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 159.59% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 152.534% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | 5771.893% |
| Akari Therapeutics, Plc | -3.84 Million USD | 1367.412% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -2902.791% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 96.471% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 4201.554% |
| UroGen Pharma Ltd. | 4.39 Million USD | -1009.816% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 57.057% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -67619.074% |
| Orgenesis Inc. | 21.78 Million USD | -123.705% |
| Entera Bio Ltd. | -10.62 Million USD | 558.482% |
| GH Research PLC | -78.07 Million USD | 162.415% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 318.647% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 282.798% |
| Xencor, Inc. | 29.64 Million USD | -64.391% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 2573.942% |
| Replimune Group, Inc. | 1.41 Million USD | -3351.275% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | 19998.084% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 138.549% |
| Lexaria Bioscience Corp. | -1.18 Million USD | 4201.554% |
| Portage Biotech Inc. | -4.98 Million USD | 1078.358% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | 216734.808% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 173.7% |
| OncoCyte Corporation | -6.56 Million USD | 842.526% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | -5330.276% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 1169.706% |
| Purple Biotech Ltd. | -14.13 Million USD | 444.688% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 305.136% |
| scPharmaceuticals Inc. | -6.54 Million USD | 844.568% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 391.945% |
| HilleVax, Inc. | -165.48 Million USD | 129.448% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 2020.095% |
| Tharimmune, Inc. | -10.93 Million USD | 545.637% |
| Genprex, Inc. | -6.73 Million USD | 823.281% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 113.213% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 155.089% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | 3578.373% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 1569.183% |
| OKYO Pharma Limited | -826.84 Thousand USD | 5993.707% |
| Savara Inc. | 153 Thousand USD | -31750.98% |
| Curis, Inc. | -23.88 Million USD | 304.011% |
| Daré Bioscience, Inc. | -5.15 Million USD | 1044.801% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | 6379.8% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 884.987% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | -4012.405% |
| BeiGene, Ltd. | -2.25 Billion USD | 102.163% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | -294.959% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 108.012% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 126.258% |
| Erasca, Inc. | -37.21 Million USD | 230.944% |
| bluebird bio, Inc. | 108.57 Million USD | 55.115% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 3883.855% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 87.133% |
| DBV Technologies S.A. | -126.98 Million USD | 138.376% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | 3883.855% |
| Moderna, Inc. | -2.9 Billion USD | 101.676% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 570.75% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 548.399% |
| Molecular Templates, Inc. | 707 Thousand USD | -6792.786% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 255.341% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 85.94% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 159.384% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 153.125% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 251.004% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 241.762% |
| MacroGenics, Inc. | -66.98 Million USD | 172.751% |
| RenovoRx, Inc. | -1.17 Million USD | 4254.476% |
| Adicet Bio, Inc. | -138.78 Million USD | 135.113% |
| Prime Medicine, Inc. | -27.94 Million USD | 274.41% |
| Aditxt, Inc. | 18.12 Million USD | -168.927% |
| Adagene Inc. | -87.62 Million USD | 155.613% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 1269.916% |
| Quantum-Si incorporated | -118.55 Million USD | 141.104% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | -35.348% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 752.004% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 200.46% |
| SciSparc Ltd. | -2.06 Million USD | 2459.903% |
| Vericel Corporation | 1.27 Million USD | -3716.132% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 506.381% |
| Minerva Neurosciences, Inc. | 41 Million USD | -18.846% |
| Generation Bio Co. | 31.44 Million USD | -54.961% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 127.789% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 257.591% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 58.203% |
| Invivyd, Inc. | -198.47 Million USD | 124.553% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 153.985% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 2132.458% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 168.84% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 814.022% |
| 2seventy bio, Inc. | 181.71 Million USD | 73.182% |
| ADMA Biologics, Inc. | 90.06 Million USD | 45.893% |
| Clene Inc. | 3.34 Million USD | -1359.042% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 636.536% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 326.545% |
| GeoVax Labs, Inc. | -6.45 Million USD | 855.232% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 114.161% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 287.433% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 72.571% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 1291.035% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -874.25% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 1035.535% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 137.399% |
| Evaxion Biotech A/S | 5.28 Million USD | -821.76% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 143.291% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 137.123% |
| Trevena, Inc. | 2.25 Million USD | -2058.193% |
| Surrozen, Inc. | -32.66 Million USD | 249.192% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 194.607% |
| Cingulate Inc. | 3.08 Million USD | -1480.831% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 1759.244% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -578.058% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 624.495% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 161.435% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 137.072% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 146.173% |
| Clearmind Medicine Inc. | -3.94 Million USD | 1336.026% |
| Kronos Bio, Inc. | -36.05 Million USD | 235.164% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | -417.93% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -3242.096% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 189.819% |
| Statera Biopharma, Inc. | 14.41 Million USD | -238.032% |
| ImmunityBio, Inc. | 618.22 Million USD | 92.117% |
| Korro Bio, Inc. | -132.94 Million USD | 136.656% |
| Kineta, Inc. | -4.54 Million USD | 1173.156% |
| BioVie Inc. | -17.73 Million USD | 374.82% |
| Codexis, Inc. | -43.27 Million USD | 212.62% |
| Celularity Inc. | 65.19 Million USD | 25.246% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 1637.772% |
| Celcuity Inc. | 6.78 Million USD | -618.389% |
| Virax Biolabs Group Limited | -3.36 Million USD | 1548.226% |
| Cibus, Inc. | -8.07 Million USD | 703.268% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 1252.329% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -966.346% |
| IN8bio, Inc. | -16.38 Million USD | 397.346% |
| Kodiak Sciences Inc. | -103.87 Million USD | 146.914% |
| Annexon, Inc. | -193.75 Million USD | 125.151% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | -135266.667% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 378.484% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 1487.19% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 95.378% |
| Eyenovia, Inc. | 1.25 Million USD | -3771.607% |
| Puma Biotechnology, Inc. | 26.9 Million USD | -81.126% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 1602.683% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 246.576% |
| Arcellx, Inc. | -296.95 Million USD | 116.41% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 349.831% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 182.772% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 335.114% |
| Moolec Science SA | 117.61 Thousand USD | -41333.138% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 226.91% |
| Geron Corporation | 14.76 Million USD | -230.14% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 228.519% |
| Royalty Pharma plc | 5.65 Billion USD | 99.139% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 134.459% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 797.225% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 1008.694% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 134.628% |
| Humacyte, Inc. | -22.48 Million USD | 316.722% |
| Structure Therapeutics Inc. | -124.33 Million USD | 139.193% |
| 89bio, Inc. | -289.05 Million USD | 116.859% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 293.059% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 2833.146% |
| Genelux Corporation | -6.89 Million USD | 806.363% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 256.901% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 41.707% |
| Notable Labs, Ltd. | -9.77 Million USD | 598.486% |
| Liquidia Corporation | -80.17 Million USD | 160.781% |
| Mustang Bio, Inc. | -3.73 Million USD | 1404.39% |
| Immunovant, Inc. | -635.22 Million USD | 107.672% |
| Quantum-Si incorporated | -118.55 Million USD | 141.104% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 377.454% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 1276.249% |
| Vera Therapeutics, Inc. | 8.02 Million USD | -507.101% |
| Acasti Pharma Inc. | -23 Million USD | 311.832% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 1547.243% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 399.901% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 135.38% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 1663.746% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 319.198% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 362.437% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 128.788% |
| PepGen Inc. | -60.67 Million USD | 180.323% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 312.1% |
| United Therapeutics Corporation | -507.7 Million USD | 109.599% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 354.795% |
| Solid Biosciences Inc. | -47.75 Million USD | 202.057% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | 5752.781% |
| Immuneering Corporation | -54.94 Million USD | 188.696% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 1259.323% |
| Silo Pharma, Inc. | -3.52 Million USD | 1482.74% |
| Belite Bio, Inc | -87.27 Million USD | 155.84% |
| XOMA Corporation | -29 Million USD | 268.041% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 168.931% |
| Bionomics Limited | 227 Million USD | 78.533% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 141.908% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 2023.885% |
| uniQure N.V. | -102.95 Million USD | 147.335% |
| Cassava Sciences, Inc. | -121.13 Million USD | 140.229% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 1269.916% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | -19.001% |
| Forte Biosciences, Inc. | -11.96 Million USD | 507.424% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 1674.947% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | -45873.585% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 1602.683% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | -447.243% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 757.12% |
| Altimmune, Inc. | -134.48 Million USD | 136.235% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 75.396% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 2023.885% |
| Compugen Ltd. | -12.9 Million USD | 477.65% |
| Peak Bio, Inc. | 10.34 Million USD | -371.289% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | 17319.788% |
| Benitec Biopharma Inc. | -50.58 Million USD | 196.343% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 146.706% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | -148.063% |
| Zura Bio Limited | -99.8 Million USD | 148.827% |
| PolyPid Ltd. | 6.17 Million USD | -689.822% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 34.253% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | -148.063% |
| Instil Bio, Inc. | 75.35 Million USD | 35.333% |
| argenx SE | -2.02 Billion USD | 102.402% |
| Immunome, Inc. | -97.02 Million USD | 150.224% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 316.635% |
| Verona Pharma plc | -220.44 Million USD | 122.106% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 167.926% |
| Shattuck Labs, Inc. | -121.42 Million USD | 140.134% |
| CervoMed Inc. | -7.79 Million USD | 725.343% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 126.271% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 1214.384% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 136.991% |
| Moolec Science SA | 117.61 Thousand USD | -41333.138% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 2229.917% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | -206.522% |
| AnaptysBio, Inc. | -18.15 Million USD | 368.481% |
| Design Therapeutics, Inc. | -18.15 Million USD | 368.496% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 169.24% |
| NeurAxis, Inc. | 145.7 Thousand USD | -33346.809% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | -333.868% |
| Lumos Pharma, Inc. | -28.49 Million USD | 271.031% |
| Achilles Therapeutics plc | -126.92 Million USD | 138.395% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 167.926% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | 7531.717% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 334.584% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | -3242.096% |
| Nutriband Inc. | -251.65 Thousand USD | 19464.452% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 469.995% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 755.0% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 85.675% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | -105.317% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 110.891% |
| Palisade Bio, Inc. | -12.06 Million USD | 503.979% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 134.731% |
| Beam Therapeutics Inc. | -262.72 Million USD | 118.549% |
| Neurogene Inc. | -131.95 Million USD | 136.931% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | -123.377% |
| AEON Biopharma, Inc. | -4.88 Million USD | 1098.607% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 112.92% |
| Sesen Bio, Inc. | -112.55 Million USD | 143.297% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 148.8% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 2175.651% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 224.871% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 158.514% |
| Athira Pharma, Inc. | -88.99 Million USD | 154.756% |
| Vaccinex, Inc. | -1.28 Million USD | 3883.54% |
| HCW Biologics Inc. | 2.85 Million USD | -1605.899% |
| XOMA Corporation | -29 Million USD | 268.041% |
| Nektar Therapeutics | 210.24 Million USD | 76.821% |
| Arvinas, Inc. | -313.8 Million USD | 115.53% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | -2902.791% |
| Merus N.V. | -192.88 Million USD | 125.265% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 18.76% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 802.393% |
| Rezolute, Inc. | -68.16 Million USD | 171.488% |
| Clene Inc. | 3.34 Million USD | -1359.042% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 469.546% |
| BeyondSpring Inc. | -13.75 Million USD | 454.286% |
| Synlogic, Inc. | -6.68 Million USD | 828.975% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | -4197.354% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 676.369% |
| Peak Bio, Inc. | 10.34 Million USD | -371.289% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 159.126% |
| Krystal Biotech, Inc. | -350.23 Million USD | 113.914% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 60.74% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 128.836% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 1643.547% |
| MannKind Corporation | 143.89 Million USD | 66.135% |
| Ikena Oncology, Inc. | -109.15 Million USD | 144.644% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 743.667% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 247.227% |
| Gossamer Bio, Inc. | 180.35 Million USD | 72.98% |
| CohBar, Inc. | -5.93 Million USD | 921.686% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 263.816% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | -967.28% |
| Legend Biotech Corporation | -949.39 Million USD | 105.133% |
| Mural Oncology plc | -255.84 Million USD | 119.048% |
| Biora Therapeutics, Inc. | 32.21 Million USD | -51.271% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 1134.509% |
| Disc Medicine, Inc. | -358.28 Million USD | 113.602% |
| Champions Oncology, Inc. | 4.81 Million USD | -912.718% |
| REGENXBIO Inc. | 54.76 Million USD | 11.021% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | 18222.25% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 132.268% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 640.745% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 160.399% |
| Vaxart, Inc. | -8.24 Million USD | 691.336% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 197.114% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 138.322% |
| Cellectis S.A. | -43.85 Million USD | 211.121% |
| Longeveron Inc. | -2.9 Million USD | 1775.791% |
| Repare Therapeutics Inc. | -107.85 Million USD | 145.182% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 94.968% |
| Inozyme Pharma, Inc. | 12 Million USD | -305.965% |
| Revolution Medicines, Inc. | -608.2 Million USD | 108.012% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | 4061.951% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 118.381% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 132.472% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 411.446% |
| Anixa Biosciences, Inc. | -740 Thousand USD | 6685.405% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 100.51% |
| Denali Therapeutics Inc. | -74.86 Million USD | 165.093% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 506.381% |
| Veru Inc. | 4.77 Million USD | -919.505% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 533.327% |
| Cingulate Inc. | 3.08 Million USD | -1480.831% |
| Passage Bio, Inc. | 4.58 Million USD | -962.857% |
| Context Therapeutics Inc. | -14.44 Million USD | 437.25% |
| Exicure, Inc. | 5.84 Million USD | -733.168% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 121.153% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 223.154% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | -210.573% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 182.848% |
| Nuvalent, Inc. | -335.38 Million USD | 114.53% |
| ABVC BioPharma, Inc. | 1.73 Million USD | -2709.828% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 165.428% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 648.166% |
| OmniAb, Inc. | 9.2 Million USD | -429.523% |
| Anew Medical, Inc. | 1.43 Million USD | -3301.968% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | -197.477% |
| Lipocine Inc. | -4.75 Million USD | 1124.946% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 144.371% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | -219.953% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 196.196% |
| G1 Therapeutics, Inc. | 24.89 Million USD | -95.774% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 825.071% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 174.03% |
| Ocugen, Inc. | -32.52 Million USD | 249.848% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 156.947% |
| Q32 Bio Inc. | -37.94 Million USD | 228.418% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | 7859.873% |
| Alumis Inc. Common Stock | -13.52 Million USD | 460.204% |
| Equillium, Inc. | -22.39 Million USD | 317.631% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 290.598% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 249.362% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | 19756.737% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 63.644% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -1423.827% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -14737.368% |
| Dominari Holdings Inc. | 195 Thousand USD | -24890.769% |
| Edesa Biotech, Inc. | -5.26 Million USD | 1025.248% |
| vTv Therapeutics Inc. | -8.91 Million USD | 646.507% |
| Bio-Techne Corporation | 267.74 Million USD | 81.799% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 400.648% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 141.265% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 679.936% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 485.203% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 119.881% |
| Nkarta, Inc. | 57.29 Million USD | 14.951% |
| BioCardia, Inc. | 212 Thousand USD | -22886.792% |
| Iterum Therapeutics plc | 13.43 Million USD | -262.643% |